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ABSTRACT 
Objective: The aim of the present study was to formulate the oro dispersible tablets (ODTs) of Orlistat (OST) by direct compression technique using 
melt granulation method.  
Methods: Super disintegrants were used for the preparation of ODTs namely Crospovidone (CP), Croscarmellose sodium (CCS), Sodium starch 
glycolate (SSG). The powder mixture was subjected to pre compression evaluation like FTIR, Micromeritic, solubility studies and post-compression 
evaluation like friability, hardness, wetting time, dispersion time, disintegration time and in vitro dissolution rate.  
Results: FTIR studies confirmed that there was no chemical interaction between the drug and excipients. Micromeritic studies revealed that the 
powder blend has good flow ability. The results of hardness and friability complied with the official standards. The solid dispersions (SDs) prepared 
in OST to PEG 6000 ratio of 1:2 were showed good solubility than other SDs and it was selected for formulation development. It was evident from 
the results that the increase in super disintegrants concentration decreases the wetting, dispersion and disintegration times and CP showed the best 
results than other super disintegrating agents.  
Conclusion: The F4 formulation showed optimum drug release of 98.99 % at the end of 15 min when compared to the other formulations; it might 
be due to the presence of CP. 
Keywords: Direct compression, Melt granulation method, Orlistat, Orodispersible tablets, Polyethylene glycol.  
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INTRODUCTION 
Oral administration is the most popular route. About 50-60 % of 
total dosage forms are administered due to ease of ingestion, pain 
avoidance, versatility (to accommodate various types of drug 
candidates) and most significantly patient compliance [1, 2]. Solid 
oral drug delivery systems do not require sterile conditions and are 
therefore less expensive to fabricate [2-4]. One important drawback 
of solid dosage forms is the difficulty in swallowing (dysphasia) or 
chewing in some patients particularly pediatric [5] and geriatric 
patients [6]. The problem of swallowing is a common phenomenon 
in geriatric patients because of fear of choking, hand tremors, 
dysphasia and in children due to underdeveloped muscular and 
nervous systems.  
Difficulties in swallowing of tablets and capsules also arise whilst 
water is not available like in diarrhea, coughing during the common 
cold, allergic conditions and bronchial infections [7]. Oral fast-
dissolving drug delivery system (OFDDS) is the one that can increase 
the patient acceptance by the way of distinctive feature i. e. rapid 
disintegration and self-administration without water or chewing. 
Orally disintegrating tablets (ODTs) are solid unit dosage forms like 
conventional tablets but are composed of super disintegrants, which 
help them to disintegrate the tablet rapidly in saliva without the need 
to take it with water. ODTs are not only indicated for people who have 
swallowing difficulties but also ideal for active people [8, 9].  
Orally disintegrating drug delivery systems can be prepared by the 
techniques or methods like sublimation [8, 10-13],spray drying [13-
16],effervescent method [12, 17-19], lyophilization or freeze drying 
[13, 20, 21], melt granulation [8, 16, 22, 23], solvent evaporation [5, 
24, 25], direct compression [8, 11-13, 26-30], kneading technique 
[31], molding [8, 13, 16], cotton candy process [13], nanonization 
[13], crystalline transition process [8], phase transition [8], 
compaction [8, 16], flat heat process [16], one step dry coated tablet 
technology [32], suspension spray coating method [33] using super 
disintegrants and some other co-processed excipients [25]. 
OST i. e. (S)-(S)-1-((2S,3S)-3-Hexyl-4-oxooxetan-2-yl) tridecan-2-yl) 
2-formamido-4-methylpentanoate is drug which has been designed 
to treat the disease obesity by reversible inhibition of lipases 
thereby reduces the caloric intake [34, 35] and advised to give adults 
along with the reduced calorie diet [36]. It also has an effect on 
reducing the blood pressure and type-2 diabetes [37]. OST comes 
under the BCS classification class-II drug i. e. low aqueous solubility 
and high permeability. Formulation additives and characteristics 
play a vital role on drug dissolution rate and bioavailability of poorly 
soluble drugs [38]. Based on these considerations, to enhance the 
bioavailability of OST, it was proposed to formulate the ODTs of OST 
by direct compression technique using the melt granulation method. 
Literature also revealed that there was no work reported on the 
formulation of OST ODTs by melt granulation method. Hence, the 
attempt was made to formulate the OST ODTs by melt granulation 
method.  
MATERIALS AND METHODS 
Materials 
OST purchased from RA Chem Pvt. Ltd., Hyderabad, India and PEG 
6000, PEG 4000, PEG 1000, CP, CCS, SSG, Talc from S. D. Fine Chem. 
Ltd, Mumbai, India, Mannitol from Finar Chemical Ltd., Ahmadabad, 
India, Aspartame, Sodium stearyl fumarate (SSF) from Active 
pharma labs, Hyderabad, India.  
Methods  
Preparation of orlistat solid dispersions by melt granulation 
method 
SDs of OST in drug to carrier ratio of 1:1, 1:2, 1:3 were prepared by 
melt granulation method using PEG 1000, PEG 4000 and PEG 6000 
separately. The accurately weighed amount of carrier was melted in 
china dish in a water bath, and then the calculated amount of OST 
was added with thorough mixing for at least 1-2 min until to reach 
homogeneity. Then these melted mixtures were allowed to cool, 
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followed by drying and the dried product was then made to undergo 
pulverization by passing through the sieve no.60 and stored in a 
desiccator for further studies (Table 1). Based on the results from 
solubility studies, the best composition of drug and carrier was 
selected for formulation development [6].  
 
Table 1: Composition of OST SDs 
Solid dispersions  Drug-carrier ratio 
Orlistat: PEG 6000 1:1 
1:2 
1:3 
Orlistat: PEG 4000 1:1 
1:2 
1:3 




Preparation of OST ODTs 
ODTs of OST were prepared by direct compression method by using 
super disintegrating like CP, CCS, and SSG in different concentrations 
(Table 2). Based on the solubility studies, the SDs of OST: PEG 6000 
in the ratio of 1:2 was optimized for the preparation of ODTs. All the 
formulations consist of Mannitol, Aspartame, Orange flavor, Talc, 
SSF and their use as a diluents, sweetener, and flavor, glidant, 
lubricant respectively. All the excipients of required quantity were 
blended with OST SDs in a dried mortar for 10 min except SSF and 
Talc. Prior to compression, SSF and talc were added and mixed 
gently for 2-3 min. The tablets were punched with BB Tooling in 
rotary tablet punching machine of 9 mm punch size and the 
compression force adjusted to give the hardness of official range of 
2-4 kg/cm3 [38]. 
FTIR studies 
The pure OST (drug) and its physical mixture were subjected to IR 
spectral studies by employing the KBr pellet method using FTIR 
spectrophotometer (Model-IR Affinity-1, Shimadzu, Japan). One to 
two milligram of fine solid powder of OST and 200-300 mg of dry 
powder of KBr (IR grade) were taken in a mortar and mixed well 
with the help of the spatula. Spectrum measurement was carried out 
using KBr disk method in the wavelength region of 4000-400 cm-1 by 
FTIR spectrophotometer. The spectra obtained for OST, and the 
physical mixture was compared. 
Micromeritic study 
The pre compression parameters like bulk and tapped density [39], 
the angle of repose [40], Hausner’s ratio and Carr’s index [41] were 
carried out for powder mixture according to the standard 
procedures.
  
Table 2: Formulations of OST ODTs with PEG 6000 (1:2) 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 









- - - - - - - - 








- - - - 








Mannitol 51 46 41 36 51 46 41 36 51 46 41 36 
Aspartame 10 10 10 10 10 10 10 10 10 10 10 10 
Orange flavor 1 1 1 1 1 1 1 1 1 1 1 1 
Talc 2 2 2 2 2 2 2 2 2 2 2 2 
SSF 1 1 1 1 1 1 1 1 1 1 1 1 
Total weight (mg) 250 250 250 250 250 250 250 250 250 250 250 250 
 
Solubility studies of OST SDs  
A known excess amount (12 mg) of OST SDs prepared with PEG 
1000, PEG 4000, PEG 6000 in drug to carrier ratio of 1:1, 1:2, 1:3 
was transferred individually into an individual boiling tubes 
containing 10 ml of water to form a saturated solution. Then these 
solutions were kept for shaking on cyclomixer. After 24 h, the 
samples were subjected to centrifugation and the supernatant was 
collected, suitably diluted, estimated for OST concentration using 
UV-Visible spectrophotometer (Lab India 1700 UV-Visible 
spectrophotometer) at 215 nm.  
Post compression evaluation  
Post-compression parameters like friability, hardness, thickness, 
weight variation, content uniformity, disintegration tests were 
evaluated for the tablets according to the standard procedures [4, 42].  
Wetting time and water absorption ratio (R) 
Five circular tissue papers in 10 cm in diameter were placed in a 
Petri dish containing 10 ml water soluble dye i. e. eosin and this dye 
solution helps to know the complete wetting of tablet surface. A 
tablet was carefully placed on the surface of tissue paper in the Petri 
dish at room temperature. The time required for water to reach the 
upper surface of the tablet and completely wet them was noted as 
the wetting time [43]. To check for reproducibility, the 
measurements were carried out in replicates (n=3). The wetting 
time was recorded using a stopwatch. 
The weight of the tablet before keeping in Petri dish was noted (Wb) 
using Shimadzu digital balance. The wetted tablet from the Petri 
dish was taken and reweighed (Wa) using the same. The Water 







Wb and Wa are the weight before and after water absorption 
respectively.  
In-vitro dissolution study 
The dissolution test was carried out using Electro lab TDT-06N USP 
dissolution test apparatus type-II (Paddle method). 900 ml of pH 6.8 
phosphate buffers was placed in a vessel and the medium was 
allowed to equilibrate to the temperature of 37°C ± 0.5°C and set to 
rotate about 50rpm. The tablet was placed in the vessel and 
operated for about 30 min. At definite time intervals (2, 4, 6, 8, 10, 
15, 20, 25, 30 min), 5 ml of sample was withdrawn, filtered and 
again 5 ml of fresh buffer was replaced.  
Suitable dilutions were done with the buffer solution and analyzed 
by spectrophotometrically at 215 nm using UV-Visible 
spectrophotometer (Lab India 1700 UV-Visible spectrophotometer). 
Each dissolution study was performed for three times, and mean 
values were taken. 
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Stability studies 
From the obtained results that the formulation F4 was selected for 
stability studies, and it was performed at 40 oC/75 % RH for about 3 
months. The tablets were analyzed for drug content uniformity and 
hardness at the end of each month for up to 3 months [44].  
RESULTS AND DISCUSSION 
FTIR studies 
It was performed to know the compatibility between the drug and 
excipients. The IR spectra of OST physical mixture was 
demonstrated in Figure 1 and summarized in Table. 3. All the 
characteristic peaks of OST were presented in IR spectra of its 
physical mixture indicates that there is no reciprocal action between 
the drug and excipients. 
Micromeritic study  
Hausner’s ratio was carried out, and it was found to be between 1.20 
to 1.23, the results were indicated that the powder blends have good 
flow properties for compression. Carr’s index was ranged from 
10.66 to 19.02, indicates that the powder blends have good to fair 
flow ability for compression. The angle of repose was found to be 
290 to 320,  the results were indicated that the powder blends have 
good flow properties (table 4). 
  
Table 3: Interpretation of IR spectra of optimized formulation (F4) 
Functional group Standard range (cm-1) Orlistat pure drug (cm-1) Orlistat mixture  (cm-1) 
C–H stretching in CH2 2850-2960 2927 2958 
N–H stretching 3500-3300 3300 3309 
C=C aromatic stretching 1450-1600 1500 1587 
 
 
Fig. 1: FTIR spectra of optimized formulation (F4) 
 
Table 4: Pre compression characteristics of OST ODTs 
Formulation Bulk density (gm/ml) 
Avg ± SD (n=3) 
Tapped density 
(gm/ml) 
Avg ± SD (n=3) 
Hausners ratio 
Avg ± SD (n=3) 
Compressibility index ( %) 
Avg ± SD (n=3) 
Angle of 
repose (Ө) 
Avg ± SD (n=3) 
F1 0.435±0.02 0.522±0.15 1.20±0.08 10.66±0.23 32.67±0.21 
F2 0.429±0.24 0.518±0.18 1.20±0.21 17.18±0.04 29.08±0.02 
F3 0.430±0.08 0.524±0.06 1.21±0.05 17.93±0.32 31.78±0.28 
F4 0.432±0.12 0.528±0.19 1.22±0.21 18.18±0.28 30.64±0.85 
F5 0.428±0.04 0.518±0.26 1.21±0.09 17.37±0.19 30.36±0.45 
F6 0.420±0.18 0.510±0.45 1.21±0.12 17.64±0.32 31.05±0.37 
F7 0.416±0.35 0.509±0.08 1.22±0.32 18.27±0.41 32.54±0.41 
F8 0.417±0.06 0.515±0.36 1.23±0.38 19.02±0.38 29.67±0.39 
F9 0.425±0.23 0.515±0.19 1.21±0.61 17.47±0.52 31.85±0.62 
F10 0.421±0.18 0.509±0.65 1.20±0.09 17.28±0.06 29.56±0.09 
F11 0.419±0.08 0.515±0.05 1.22±0.28 18.64±0.32 30.17±0.29 
F12 0.415±0.38 0.512±0.23 1.23±0.45 18.94±0.24 32.08±0.45 
 
Solubility studies  
The solubility of OST SDs prepared with PEG 1000, PEG 4000, PEG 
6000 were determined and it was clear from the results that the SDs 
prepared with PEG 1000 showed the least solubility and PEG 6000 
in the ratio of 1:2 showed more solubility in water compared to 
other grades of PEG, thereby it was selected for formulation 
development due to its high solubility in water (table 5). 
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Table 5: Solubility studies of OST and OST SDs prepared with PEG1000, PEG4000, PEG6000 
Formulation Solubility of OST in water (mg/ml)* 
Pure drug 0.919±0.53 












*results were expressed in Avg ± SD (n=3)  
 
Post compression studies of OST ODTs 
The hardness of all the formulations was ranged from 2.90 to 3.10 
kg/cm2 and it ensures good handling characteristics of all the 
batches. The percent friability of all the formulations was less than 
the 1 %, ensuring that the tablets were mechanically stable. All the 
prepared tablets of OST had been evaluated for weight variation. 
The weight of all the tablets was found to be uniform and was within 
the pharmacopoeial limits. The percent drug content of all the 
tablets was found to be in the range of 98.75 to 99.36 % (which was 
within the acceptable limits of ±5 %) (table 6).  
The results of in vitro disintegration time of all the tablets were 
found to be within the prescribed limits and satisfied the criteria of 
oral dispersible tablets. Among all the formulations, a formulation 
with CP (8 %) i. e. F4 showed the lower disintegration time of 27 sec 
because of among the super disintegrants, the crospovidone have 
solubility enhancing functionality in addition to the disintegration, 
dissolution enhancing capability [45, 46-48]. The wetting and 
dispersion times are most essential for ODTs and those have to be 
ideally less than 1 min. This rapid disintegration needed to assist in 
swallowing and enhancing the bioavailability in the buccal cavity 
[38]. It was clear from the results of wetting time that all the tablets 
were lies within the prescribed limits and also satisfied the criteria 
of ODTs and among all the formulations, formulation F4 showed the 
least wetting time. From the dispersion time studies, the formulation 
F4 only satisfied the criteria of ODTs i. e. dispersion time <1 min 
which facilitates the dispersion in the mouth. It was evident from the 
water absorption ratio studies that all the formulations were 
absorbed the nearly equal amount of water (table 7).  
The decrease in disintegration, wetting and dispersion times might 
be due to the presence of super disintegrants which absorbs the 
water thereby swells the tablets and causes rupture of the tablets.
  
Table 6: Post compression studies of OST ODTs 
Formulation  % Weight variation 
Avg ± SD (n=3) 
Drug content ( %) 
Avg ± SD (n=3) 
Hardness (kg/cm2) Avg ± SD 
(n=3) 
Friability ( %) Avg ± 
SD (n=3) 
Thickness (mm) 
Avg ± SD (n=3) 
F1 99.9±0.70 98.96±0.47 3.05±0.13 0.48±0.12 2.84±0.032 
F2 99.52±0.85 99±0.65 3.10±0.15 0.53±0.08 2.85±0.028 
F3 98.9±0.52 99.11±0.52 2.95±0.08 0.44±0.15 2.86±0.024 
F4 100.2±1.17 99.15±0.60 2.95±0.10 0.57±0.24 2.86±0.051 
F5 99.0±0.49 99.2±0.4 3.08±0.12 0.43±0.85 2.88±0.048 
F6 98.8±0.58 98.85±0.58 3.11±0.14 0.56±0.02 2.90±0.052 
F7 99.3±0.54 99.31±0.24 2.92±0.08 0.53±0.09 2.92±0.038 
F8 100.4±1.0 98.96±0.28 3.0±0.09 0.45±0.54 2.91±0.042 
F9 99.6±0.95 99.3±0.38 2.9±0.07 0.6±0.65 2.90±0.040 
F10 99.2±0.97 99.36±0.29 3.05±0.08 0.49±0.04 2.89±0.042 
F11 99.4±0.86 98.75±0.40 3.05±0.09 0.53±0.23 2.89±0.034 
F12 98.5±0.42 99.21±0.38 2.93±0.08 0.58±0.82 2.87±0.031 
 
Table 7: Post compression studies of OST ODTs 
Formulation Wetting time (sec) 
Avg ± SD (n=3) 
In vitro dispersion time (sec) 
Avg ± SD (n=3) 
In vitro disintegration time (sec)  
Avg ± SD (n=3) 
Water absorption ratio ( %) 
Avg ± SD (n=3) 
F1 24.83±0.98 221.33±0.13 116.5±0.37 58.45±0.02 
F2 21.16±0.75 180.5±0.24 95.16±0.75 59.25±0.23 
F3 14.66±0.51 75.11±0.89 56.50±0.64 58.9±0.09 
F4 11.66±0.51 54.10±0.63 27.83±0.16 60.65±0.12 
F5 57.33±0.81 244.5±0.09 168.83±0.94 59.88±0.32 
F6 22.33±0.36 215.5±0.54 98.12 ±0.63 61.48±0.42 
F7 28.11±0.09 177.83±0.16 73.16±0.47 59.55±0.28 
F8 19.66±0.81 126.66±0.81 36.66±0.21 60.01±0.62 
F9 37.33±0.81 259.83±0.47 171.83±0.16 64.37±0.19 
F10 28.33±0.81 225.33±0.81 153±0.89 67.54±0.05 
F11 26.66±0.81 186.83±0.75 81.5±0.24 65.50±0.23 
F12 36.83±0.16 154.5±0.83 62.66±0.75 65.89±0.41 
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In-vitro drug releases study 
All the formulations of prepared OST ODTs were subjected to in vitro 
release studies using USP dissolution apparatus type-II (paddle 
method) in pH6.8 phosphate buffer. The results obtained from 
dissolution study were summarized in Table 8 and presented in 
Figure 2. In this present study, the dissolution of OST was enhanced 
by using the super disintegrating agents in different concentrations. 
Formulations F1-F4, F5-F8 and F9-F12 were prepared by CP, CCS 
and SSG respectively. Super disintegrants can absorb the water, 
swells and rupture the tablets, thereby enhances the dissolution and 
bioavailability [38]. The formulations F1-F4, F5-F8 and F9-F12, 
showed the cumulative percent drug release (C %DR) ranged from 
95 % to 98 %, 85 % to 95 % and 85 % to 92 % respectively in 30 
min. Amongst those formulations, F1-F4 formulations made from CP 
showed highest C % DR and it might be due to its disintegrating, 
dissolution and solubility enhancing properties but other disintegrating 
agents mainly have disintegration property only. It was clear from the 
obtained results, that the concentration of disintegrating agents directly 
proportional to the dissolution rate. The formulation F4 showed C %DR 
of 98 % within 15 min. The order of increase in dissolution rate using 
different disintegrating agents: CP>SSG>CCS. 
 
Table 8: In-vitro dissolution data of OST ODT formulations 
Time 
(min) 
Cumulative % drug release (mean ± SD, n=3) 





































































































































































































Fig. 2: In-vitro drug release profiles of all the formulations 
 
Stability studies 
The tablets were analyzed for drug content uniformity, hardness, 
and this formulation didn’t show much variation in any 
parameter.  
It was evident from the obtained results that the formulation F4 
was stable and retained its original properties (table 9).  
 
Table 9: Stability studies of formulation F4 stored at 40 0C / 








± SD (n=3) 
Drug 
content Avg 
± SD (n=3) 
F4 1 2.7 ± 0.18 98.54 ± 0.11 
2 2.66 ± 0.23 97.82 ± 0.17 
3 2.65 ± 0.29 97.54 ± 0.22 
CONCLUSION 
It could be concluded from the results that the SDs prepared with 
PEG 6000 in the ratio of 1:2 (OST: PEG 6000) showed appreciable 
solubility in water than other grades of PEG. The formulation F4 
contained CP 8 % was found to be the best among all the twelve OST 
ODT formulations because it had satisfied all the limits of ODTs 
when compared to the other formulations and it showed 98.99 % 
drug release at the end of 15 min. 
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